… -based biotech describes as “unique” cancer antigens, joining the growing group … drug’s action in the tumor microenvironment could lead to better … development for ovarian and endometrial cancers. The molecule targets CD3 and … -1/VEGF play with 3SBio.

… s development into other unspecified cancer indications. Takeda will gain … Innovent’s pancreatic and gastric cancer ADC hopeful, IBI343, … advanced or metastatic solid tumours. This three-strong deal … , with the former licensing 3SBio’s bispecific, SSGJ-707, …

… with China’s 3SBio for the development of its cancer drug candidate … for non-small cell lung cancer, metastatic

… unresectable or metastatic urothelial cancer who are eligible … developing for bladder cancer Bladder cancer represents 3% of all … metastatic hormone-sensitive prostate cancer with high-risk … Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting …

In one of the biggest licensing pacts signed so far this year, GSK has put $12 billion on the line to partner with China’s Hengrui Pharma and advance up to 12 novel therapies for respiratory, immunology and oncology indications. The collaboration, …

… the global licensing agreement with 3SBio, Inc. With this agreement … develop, manufacture, and commercialize 3SBio’s SSGJ-707, a … its competitive edge in cancer research. The antibody is … clinical trials for gynecological tumors. By manufacturing the drug …

… deal with Chinese biotech firm 3SBio, marking the biggest transaction in … development, manufacturing, and commercialization of 3SBio’s promising drug, SSGJ-707 … cell lung cancer (NSCLC), metastatic colorectal cancer, and various gynecological cancers. The drug …

… deal with Chinese biotech firm 3SBio, marking the biggest transaction in … development, manufacturing, and commercialization of 3SBio’s promising drug, SSGJ-707 … cell lung cancer (NSCLC), metastatic colorectal cancer, and various gynecological cancers. The drug …

… its licensing agreement with 3SBio that grants Pfizer … which was developed using 3SBio’s proprietary CLF2 platform … for a variety of cancers. 3SBio will receive $1.25 … cell lung cancer (NSCLC), metastatic colorectal cancer, and gynecological tumors. According …

… s PD-1xVEGF deal with 3SBio includes an option agreement. … a conclusion. 3. Pfizer finalizes 3SBio PD-1xVEGF deal with China … finalized its licensing deal for 3SBio’s PD-1xVEGF candidate SSGJ … #39;s Flatiron Health triples cancer network size across UK, Germany …